125 related articles for article (PubMed ID: 22704926)
1. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
Halperin SA; McNeil S; Langley JM; Smith B; MacKinnon-Cameron D; McCall-Sani R; Heyward WL; Martin JT
Vaccine; 2012 Aug; 30(36):5445-8. PubMed ID: 22704926
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
Halperin SA; Van Nest G; Smith B; Abtahi S; Whiley H; Eiden JJ
Vaccine; 2003 Jun; 21(19-20):2461-7. PubMed ID: 12744879
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of HBV vaccine during stated shelf-life.
Gloriani NG; Srinivasa K; Bock HL; Hoet B
Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
[TBL] [Abstract][Full Text] [Related]
11. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
Schiff GM; Sherwood JR; Zeldis JB; Krause DS
J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
Cooper C; Mackie D
Expert Rev Vaccines; 2011 Apr; 10(4):417-27. PubMed ID: 21506639
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
18. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
19. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.
Cooper CL; Angel JB; Seguin I; Davis HL; Cameron DW
Clin Infect Dis; 2008 Apr; 46(8):1310-4. PubMed ID: 18444872
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]